Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor therapy
Esophageal Squamous Cell Carcinoma (ESCC)
DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)|DRUG: Lenvatinib
Phase Ib：Dose Limiting Toxicities (DLTs) and recommended phase 2 dose (PR2D), Hematologic DLTs are defined as:

1. Grade 4 neutropenia lasting for ≥7 days
2. febrile neutropenia not associated with the underlying disease,
3. Grade 3 thrombocytopenia with bleeding, Grade ≥3 thrombocytopenia requiring platelet transfusion, Grade 4 thrombocytopenia, ., up to ~21 days|Phase II: Overall Survival (OS) in all participants, OS is defined as the time from the first administration to death due to any cause., up to ~48 months
PFS, PFS is defined as the time from the first administration to the first documented progressive disease (PD) per RECIST 1.1 by investigators or death due to any cause, whichever occurs first., up to ~42 months|ORR, ORR is defined as the percentage of participants with Complete Response or Partial Response per RECIST 1.1 assessed by the investigators., up to ~42 months|DOR, For participants who demonstrate a confirmed CR or PR, per RECIST 1.1 by the investigators, DOR is defined as the time from first documented evidence of CR or PR until PD or death., up to ~42 months|Number of Participants With AEs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention., Up to ~53 months
The purpose of this study is to assess the efficacy and safety of QL1706 plus lenvatinib in second-line therapy for patients with metastatic esophageal squamous cell carcinoma after progression on immune checkpoint inhibitor therapy